CD38 and acute lymphoblastic leukemia: Pre-clinical studies have shown that T-ALL blasts have cell surface expression of CD38, a transmembrane receptor expressed on thymocytes, activated T-cells, terminally differentiated B-cells but minimally expressed in normal myeloid and lymphoid cells, making it a promising therapeutic target [59].